Does the media prefer CPRX or OLMA?

In the previous week, Olema Pharmaceuticals had 4 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 5 mentions for Olema Pharmaceuticals and 1 mentions for Catalyst Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.66 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Olema Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, VKTX or OLMA?

Viking Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A

Is VKTX or OLMA more profitable?

Olema Pharmaceuticals' return on equity of -46.00% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -94.56% -82.75% Olema Pharmaceuticals N/A -46.00% -41.22%

Does the media refer more to VKTX or OLMA?

In the previous week, Viking Therapeutics had 32 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 37 mentions for Viking Therapeutics and 5 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.66 beat Viking Therapeutics' score of 0.63 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 14 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OLMA or DNLI more profitable?

Olema Pharmaceuticals' return on equity of -46.00% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -46.00% -41.22% Denali Therapeutics N/A -52.20% -43.86%

Does the media prefer OLMA or DNLI?

In the previous week, Denali Therapeutics had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 6 mentions for Denali Therapeutics and 5 mentions for Olema Pharmaceuticals. Denali Therapeutics' average media sentiment score of 1.01 beat Olema Pharmaceuticals' score of 0.66 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TNGX or OLMA more profitable?

Tango Therapeutics' return on equity of -41.54% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -41.54% -33.44% Olema Pharmaceuticals N/A -46.00% -41.22%

Does the media favor TNGX or OLMA?

In the previous week, Tango Therapeutics had 3 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 8 mentions for Tango Therapeutics and 5 mentions for Olema Pharmaceuticals. Tango Therapeutics' average media sentiment score of 1.41 beat Olema Pharmaceuticals' score of 0.66 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OGN or OLMA?

In the previous week, Organon & Co. had 7 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 12 mentions for Organon & Co. and 5 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.66 beat Organon & Co.'s score of 0.59 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Olema Pharmaceuticals (OLMA) Competitors

$11.45 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$11.44 0.00 (-0.04%)

As of 07/31/2026 07:34 PM Eastern

Compare

OLMA vs. CPRX, VKTX, DNLI, TNGX, and OGN

Should you buy Olema Pharmaceuticals stock or one of its competitors? MarketBeat compares Olema Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Olema Pharmaceuticals include Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Denali Therapeutics (DNLI), Tango Therapeutics (TNGX), and Organon & Co. (OGN).

How does Olema Pharmaceuticals compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

Catalyst Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Catalyst Pharmaceuticals currently has a consensus price target of $32.00, indicating a potential upside of 1.62%. Olema Pharmaceuticals has a consensus price target of $44.10, indicating a potential upside of 285.15%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Olema Pharmaceuticals' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

In the previous week, Olema Pharmaceuticals had 4 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 5 mentions for Olema Pharmaceuticals and 1 mentions for Catalyst Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.66 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Olema Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Catalyst Pharmaceuticals and Olema Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Viking Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Viking Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, meaning that its share price is 100% more volatile than the broader market.

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Viking Therapeutics had 32 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 37 mentions for Viking Therapeutics and 5 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.66 beat Viking Therapeutics' score of 0.63 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	14 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Olema Pharmaceuticals' return on equity of -46.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Viking Therapeutics presently has a consensus target price of $97.88, suggesting a potential upside of 208.36%. Olema Pharmaceuticals has a consensus target price of $44.10, suggesting a potential upside of 285.15%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Viking Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Olema Pharmaceuticals beats Viking Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Denali Therapeutics?

Olema Pharmaceuticals (NASDAQ:OLMA) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Olema Pharmaceuticals' return on equity of -46.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Denali Therapeutics	N/A	-52.20%	-43.86%

Olema Pharmaceuticals has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

In the previous week, Denali Therapeutics had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 6 mentions for Denali Therapeutics and 5 mentions for Olema Pharmaceuticals. Denali Therapeutics' average media sentiment score of 1.01 beat Olema Pharmaceuticals' score of 0.66 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Olema Pharmaceuticals currently has a consensus price target of $44.10, indicating a potential upside of 285.15%. Denali Therapeutics has a consensus price target of $35.17, indicating a potential upside of 52.77%. Given Olema Pharmaceuticals' higher possible upside, equities research analysts clearly believe Olema Pharmaceuticals is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Olema Pharmaceuticals has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Denali Therapeutics	$330.53M	11.05	-$512.54M	-$2.88	N/A

Summary

Olema Pharmaceuticals beats Denali Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Tango Therapeutics had 3 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 8 mentions for Tango Therapeutics and 5 mentions for Olema Pharmaceuticals. Tango Therapeutics' average media sentiment score of 1.41 beat Olema Pharmaceuticals' score of 0.66 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics presently has a consensus price target of $42.15, suggesting a potential upside of 55.09%. Olema Pharmaceuticals has a consensus price target of $44.10, suggesting a potential upside of 285.15%. Given Olema Pharmaceuticals' higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Tango Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Tango Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	63.03	-$101.59M	-$0.83	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tango Therapeutics' return on equity of -41.54% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Tango Therapeutics has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

Summary

Tango Therapeutics beats Olema Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Olema Pharmaceuticals (NASDAQ:OLMA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Organon & Co. had 7 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 12 mentions for Organon & Co. and 5 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.66 beat Organon & Co.'s score of 0.59 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 15.90%. Olema Pharmaceuticals has a consensus target price of $44.10, suggesting a potential upside of 285.15%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Organon & Co. has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.58
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Organon & Co. has a net margin of 3.41% compared to Olema Pharmaceuticals' net margin of 0.00%. Organon & Co.'s return on equity of 92.94% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	92.94%	6.04%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Organon & Co. beats Olema Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Olema Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OLMA vs. The Competition

Export

Metric	Olema Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.00B	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-5.67	7.38	282.30	24.66
Price / Sales	N/A	1,200.34	563.12	75.93
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	1.95	16.96	10.96	6.07
Net Income	-$162.45M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-4.66%	-1.77%	-0.64%	-0.44%
1 Month Performance	-9.41%	-8.39%	-5.23%	-4.81%
1 Year Performance	114.82%	48.40%	61.97%	18.61%

Olema Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OLMA Olema Pharmaceuticals	2.1335 of 5 stars	$11.45 flat	$44.10 +285.2%	+114.8%	$1.00B	N/A	N/A	70	Upcoming Earnings Gap Up
CPRX Catalyst Pharmaceuticals	3.3981 of 5 stars	$31.49 flat	$32.00 +1.6%	N/A	$3.86B	$596.96M	18.10	80	Positive News Upcoming Earnings
VKTX Viking Therapeutics	3.3756 of 5 stars	$33.02 -5.3%	$97.00 +193.8%	-2.9%	$3.84B	N/A	N/A	20	Trending News Earnings Report Analyst Revision Gap Up
DNLI Denali Therapeutics	2.8211 of 5 stars	$23.59 +0.1%	$35.17 +49.1%	+71.3%	$3.75B	$330.53M	N/A	430	Positive News Upcoming Earnings Gap Up
TNGX Tango Therapeutics	2.5698 of 5 stars	$25.75 -3.6%	$42.15 +63.7%	+316.2%	$3.70B	$62.38M	N/A	90	News Coverage Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OLMA) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. CPRX, VKTX, DNLI, TNGX, and OGN

How does Olema Pharmaceuticals compare to Catalyst Pharmaceuticals?

Summary

How does Olema Pharmaceuticals compare to Viking Therapeutics?

Summary

How does Olema Pharmaceuticals compare to Denali Therapeutics?

Summary

How does Olema Pharmaceuticals compare to Tango Therapeutics?

Summary

How does Olema Pharmaceuticals compare to Organon & Co.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. CPRX, VKTX, DNLI, TNGX, and OGN

How does Olema Pharmaceuticals compare to Catalyst Pharmaceuticals?

Which has more risk & volatility, CPRX or OLMA?

Which has better valuation and earnings, CPRX or OLMA?

Do analysts recommend CPRX or OLMA?

Do insiders and institutionals have more ownership in CPRX or OLMA?

Is CPRX or OLMA more profitable?

Does the media prefer CPRX or OLMA?

Summary

How does Olema Pharmaceuticals compare to Viking Therapeutics?

Which has stronger valuation & earnings, VKTX or OLMA?

Which has more risk & volatility, VKTX or OLMA?

Do institutionals and insiders hold more shares of VKTX or OLMA?

Does the media refer more to VKTX or OLMA?

Is VKTX or OLMA more profitable?

Do analysts rate VKTX or OLMA?

Summary

How does Olema Pharmaceuticals compare to Denali Therapeutics?

Is OLMA or DNLI more profitable?

Which has more volatility and risk, OLMA or DNLI?

Does the media prefer OLMA or DNLI?

Do insiders and institutionals believe in OLMA or DNLI?

Do analysts rate OLMA or DNLI?

Which has higher earnings and valuation, OLMA or DNLI?

Summary

How does Olema Pharmaceuticals compare to Tango Therapeutics?

Does the media favor TNGX or OLMA?

Do analysts prefer TNGX or OLMA?

Which has better valuation & earnings, TNGX or OLMA?

Do institutionals and insiders have more ownership in TNGX or OLMA?

Is TNGX or OLMA more profitable?

Which has more volatility and risk, TNGX or OLMA?

Summary

How does Olema Pharmaceuticals compare to Organon & Co.?

Does the media prefer OGN or OLMA?

Which has more volatility & risk, OGN or OLMA?

Do analysts rate OGN or OLMA?

Which has higher earnings and valuation, OGN or OLMA?

Is OGN or OLMA more profitable?

Do institutionals & insiders hold more shares of OGN or OLMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools